Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Company profile
Ticker
VRTX
Exchange
Website
CEO
Jeffrey Leiden
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vertex Pharmaceuticals (San Diego) LLC • Vertex Pharmaceuticals (Distribution) Incorporated • Vertex Pharmaceuticals (Cayman) Limited • Vertex Pharmaceuticals (Cayman III) Limited • Vertex Pharmaceuticals (Cayman 509) Limited • Vertex Pharmaceuticals (Cayman 765) Limited • Vertex Pharmaceuticals (Cayman 787) Limited • Vertex Pharmaceuticals (Delaware) LLC • Vertex Pharmaceuticals (Puerto Rico) LLC • Vertex Pharmaceuticals (Canada) Incorporated ...
IRS number
43039129
VRTX stock data
Latest filings (excl ownership)
SC TO-T
Third party tender offer statement
22 Apr 24
PX14A6G
Letter to shareholders
16 Apr 24
SC TO-C
Information about tender offer
11 Apr 24
SC TO-C
Information about tender offer
11 Apr 24
8-K
Entry into a Material Definitive Agreement
11 Apr 24
SC TO-C
Information about tender offer
10 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
10-K
2023 FY
Annual report
15 Feb 24
Transcripts
VRTX
Earnings call transcript
2023 Q4
5 Feb 24
VRTX
Earnings call transcript
2023 Q3
6 Nov 23
VRTX
Earnings call transcript
2023 Q2
1 Aug 23
VRTX
Earnings call transcript
2023 Q1
1 May 23
VRTX
Earnings call transcript
2022 Q4
7 Feb 23
VRTX
Earnings call transcript
2022 Q3
28 Oct 22
VRTX
Earnings call transcript
2022 Q2
5 Aug 22
VRTX
Earnings call transcript
2022 Q1
6 May 22
VRTX
Earnings call transcript
2021 Q4
27 Jan 22
VRTX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
BRUCE I SACHS
17 Apr 24
SC 13G/A
Capital World Investors
10 Apr 24
4
Kristen Ambrose
3 Apr 24
4
CHARLES F WAGNER JR
27 Feb 24
4
Ourania Tatsis
27 Feb 24
4
Amit Sachdev
27 Feb 24
4
Reshma Kewalramani
27 Feb 24
4
Carmen Bozic
27 Feb 24
4
Edward Morrow Atkinson III
27 Feb 24
4
Stuart A Arbuckle
27 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
66.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1151 |
Opened positions | 196 |
Closed positions | 282 |
Increased positions | 447 |
Reduced positions | 374 |
13F shares | Current |
---|---|
Total value | 62.07 tn |
Total shares | 170.72 mm |
Total puts | 582.54 k |
Total calls | 520.56 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 22.28 mm | $9.07 tn |
Capital World Investors | 21.81 mm | $8.87 tn |
FMR | 12.98 mm | $5.28 tn |
STT State Street | 12.08 mm | $4.92 tn |
T. Rowe Price | 5.89 mm | $2.40 bn |
JPM JPMorgan Chase & Co. | 5.62 mm | $2.29 tn |
Wellington Management | 5.23 mm | $2.13 tn |
Jennison Associates | 3.94 mm | $1.61 tn |
Massachusetts Financial Services | 3.63 mm | $1.48 tn |
Capital Research Global Investors | 3.57 mm | $1.45 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Sachs Bruce I | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 399.58 | 109.49 | 43.75 k | 14,853.748 |
2 Apr 24 | Kristen Ambrose | Common Stock | Sell | Dispose S | No | Yes | 419 | 240 | 100.56 k | 7,500 |
1 Apr 24 | Kristen Ambrose | Common Stock | Payment of exercise | Dispose F | No | No | 418.1 | 225 | 94.07 k | 7,740 |
26 Feb 24 | Tatsis Ourania | Common Stock | Sell | Dispose S | No | Yes | 425.7 | 354 | 150.70 k | 55,804 |
26 Feb 24 | Amit Sachdev | Common Stock | Sell | Dispose S | No | Yes | 425.7 | 3,004 | 1.28 mm | 55,325 |
23 Feb 24 | Wagner Charles F JR | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 3,309 | 1.43 mm | 53,583 |
23 Feb 24 | Tatsis Ourania | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 3,309 | 1.43 mm | 56,158 |
23 Feb 24 | Amit Sachdev | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 2,469 | 1.07 mm | 58,329 |
News
Vertex Announce Licensing Agreement And Collaboration With Treefrog Therapeutics To Optimize Production Of Vertex's Cell Therapies For Type 1 Diabetes
23 Apr 24
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday
18 Apr 24
Vertex Pharmaceuticals Announced Advancements Across Its Suzetrigine Pain Program For Acute And Neuropathic Pain
18 Apr 24
Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450
18 Apr 24
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today
16 Apr 24
Press releases
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
23 Apr 24
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
12 Apr 24
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
10 Apr 24
Vertex to Announce First Quarter 2024 Financial Results on May 6
9 Apr 24
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
1 Apr 24